Impact News +++ If You Invested $1,000 in Bank of America, Citigroup, or Wells Fargo 10 Years Ago (24/7 Wall St.) +++ CITIGROUP Aktie +3,01%

ATYR Aktie

>ATYR Aktienkurs

0.696 EUR +1.2% (TradegateBSX)

Ask: 0.708 EUR / 4300 Stück

Bid: 0.688 EUR / 4400 Stück

Tagesumsatz: 10000 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

ATYR Aktie über LYNX handeln

Intraday

1 Jahr

>ATYR Performance

1 Woche: +3,0%

1 Monat: -5,6%

3 Monate: +7,1%

6 Monate: -4,9%

1 Jahr: -73,8%

laufendes Jahr: +7,9%

>ATYR Aktie

Name:

ATYR PHARMA INC. DL -,001

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US0021202025 / A2PM86

Symbol/ Ticker:

471A (Frankfurt) / ATYR (NASDAQ)

Kürzel:

FRA:471A, ETR:471A, 471A:GR, NASDAQ:ATYR

Index:

Webseite:

https://www.atyrpharma.co..

Profil:

Atyr Pharma Inc. is a clinical-stage biotechnology company focused on discovering and developing first-in-class medicines derived from its proprietary tRNA synthetase platform. The company translates tRNA synthetase biology into therapies targeting f..
>Volltext..

Marktkapitalisierung:

69.19 Mio. EUR

Unternehmenswert:

12.94 Mio. EUR

Umsatz:

0.16 Mio. EUR

EBITDA:

-65.15 Mio. EUR

Nettogewinn:

-63.47 Mio. EUR

Gewinn je Aktie:

-0.68 EUR

Schulden:

10.3 Mio. EUR

Liquide Mittel:

9.2 Mio. EUR

Operativer Cashflow:

-53.08 Mio. EUR

Bargeldquote:

5.19

Umsatzwachstum:

-28.74%

Gewinnwachstum:

-2.04%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

ATYR

Letzte Datenerhebung:

08.04.26

>ATYR Kennzahlen

Aktien/ Unternehmen:

Aktien: 98.05 Mio. St.

Frei handelbar: 97.5%

Leerverk. Aktien: 19.34%

Rückkaufquote: -82.37%

Mitarbeiter: 58

Umsatz/Mitarb.: -

Analysten:

Analystenrating: Buy

Kursziel: 413.79%

Bewertung:

KGV: -

KGV lG: -

KUV: 389.84

KBV: 1.25

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: -717.37%

Gewinnmarge: -39009.47%

Operative Marge: -40856.32%

Managementeffizenz:

Gesamtkaprendite: -77.12%

Eigenkaprendite: -107.81%

>ATYR Peer Group

Gesundheit, Lungenerkrankungen & -behandlung/ Asthma, Lebererkrankungen & -behandlung/ Hepatitis

>ATYR Chart & Kurs - NASDAQ

>ATYR News

06.03.26 - 07:30	aTyr Pharma GAAP EPS of -$0.14 beats by $0.02 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

05.03.26 - 22:03	aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update (GlobeNewswire EN)
	aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update...

20.02.26 - 22:03	aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire EN)
	aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)...

18.02.26 - 14:03	aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference (GlobeNewswire EN)
	aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference...

06.02.26 - 15:36	Weekly Buzz: ATYR To Meet With FDA, SGMO Aces Fabry Study, AQST′s Anaphylm Gets Rejected (AFX)
	PETAH TIKVA (dpa-AFX) - This week's biotech landscape witnessed key FDA meetings being scheduled, IND clearances, complete response letters, sale of oncology assets and clinical trial data readout......

05.02.26 - 03:02	Insiderhandel: President and CEO verkauft Aktien von aTyr Pharma im Wert von 3655 USD (Insiderkauf)
	Shukla, Sanjay - Vorstand - Tag der Transaktion: 2026-02-04...

05.02.26 - 03:02	Insiderhandel: Chief Financial Officer verkauft Aktien von aTyr Pharma im Wert von 1521 USD (Insiderkauf)
	Church, Jill Marie - Vorstand - Tag der Transaktion: 2026-02-04...

05.02.26 - 03:02	Insiderhandel: General Counsel verkauft Aktien von aTyr Pharma im Wert von 1091 USD (Insiderkauf)
	Krueger, Nancy - Vorstand - Tag der Transaktion: 2026-02-04...

03.02.26 - 19:18	aTyr Pharma to meet FDA in April to discuss lead asset (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

03.02.26 - 14:03	aTyr Pharma Announces Scheduling of FDA Type C Meeting to Discuss Efzofitimod Program in Pulmonary Sarcoidosis (GlobeNewswire EN)
	aTyr Pharma Announces Scheduling of FDA Type C Meeting to Discuss Efzofitimod Program in Pulmonary Sarcoidosis...

15.12.25 - 20:54	Johnson Fistel Investigates Claims on Behalf of aTyr Pharma, Inc. (ATYR) Shareholders (PR Newswire)
	SAN DIEGO, Dec. 15, 2025 /PRNewswire/ -- Johnson Fistel, PLLP is investigating potential derivative claims on behalf of aTyr Pharma, Inc. (NASDAQ: ATYR) concerning alleged fiduciary breaches tied to disclosures around the Phase 3 EFZO-FIT clinical trial. The relevant class action covers......

09.12.25 - 03:00	ATYR Deadline: ATYR Investors with Losses Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit (PR Newswire)
	NEW YORK, Dec. 8, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of aTyr Pharma, Inc. (NASDAQ: ATYR) between January 16, 2025 and September 12, 2025, both dates inclusive (the "Class Period"), of the important December 8,......

08.12.25 - 09:27	aTyr Pharma, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - ATYR (PR Newswire)
	LOS ANGELES, Dec. 8, 2025 /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of aTyr Pharma, Inc. ("aTyr" or "the Company") (NASDAQ: ATYR) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses on whether the......

08.12.25 - 08:18	ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm (PR Newswire)
	LOS ANGELES, Dec. 8, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against aTyr Pharma, Inc. ("aTyr" or "the Company") (NASDAQ: ATYR) for violations of §§10(b) and 20(a) of the Securities Exchange Act......

05.12.25 - 21:33	Investors who lost money on aTyr Pharma, Inc.(ATYR) should contact Levi & Korsinsky about pending Class Action - ATYR (PR Newswire)
	NEW YORK, Dec. 5, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in aTyr Pharma, Inc. ("aTyr" or the "Company") (NASDAQ: ATYR) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of aTyr investors who were adversely affected......

05.12.25 - 18:03	aTyr Pharma Inc. (ATYR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit (PR Newswire)
	BENSALEM, Pa., Dec. 5, 2025 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against aTyr Pharma Inc. ("aTyr" or the "Company") (NASDAQ: ATYR). IF YOU ARE AN INVESTOR WHO......

05.12.25 - 14:06	ATYR 3-DAY DEADLINE ALERT: Hagens Berman Urges aTyr Pharma Investors to Act by Dec. 8 Deadline in Suit Over Trial Failure (PR Newswire)
	Securities Class Action Pending Over Key Drug's Efficacy SAN FRANCISCO, Dec. 5, 2025 /PRNewswire/ -- Global plaintiffs' rights law firm Hagens Berman reminds investors of the December 8, 2025, deadline to move the Court for appointment as lead plaintiff in the securities class action......

04.12.25 - 16:57	INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma (PR Newswire)
	Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In aTyr To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in aTyr between January 16, 2025 and September 12, 2025 and would like to......

04.12.25 - 13:51	ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm (PR Newswire)
	LOS ANGELES, Dec. 4, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against aTyr Pharma, Inc. ("aTyr" or "the Company") (NASDAQ: ATYR) for violations of §§10(b) and 20(a) of the Securities Exchange Act......

04.12.25 - 13:51	aTyr Pharma, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - ATYR (PR Newswire)
	LOS ANGELES, Dec. 4, 2025 /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of aTyr Pharma, Inc. ("aTyr" or "the Company") (NASDAQ: ATYR) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses on whether the......

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Es geht uns schlecht und wird erst besser werden, wenn unsere Philosophen mehr von der Welt und unsere Welt mehr von den Philosophen wissen wird. - Freifrau Marie von Ebner-Eschenbach

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram